Analysts Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Target Price at $60.86

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have earned a consensus recommendation of “Buy” from the nine ratings firms that are covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $60.8571.

A number of research firms have recently commented on KNSA. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Monday, May 4th. Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, June 8th. Finally, Wedbush increased their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, April 29th.

Kiniksa Pharmaceuticals International Price Performance

KNSA opened at $55.11 on Wednesday. Kiniksa Pharmaceuticals International has a twelve month low of $26.27 and a twelve month high of $59.87. The company has a 50-day simple moving average of $51.02 and a 200 day simple moving average of $46.34. The stock has a market capitalization of $4.24 billion, a price-to-earnings ratio of 61.23 and a beta of 0.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. The firm had revenue of $214.27 million during the quarter, compared to analysts’ expectations of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.11 earnings per share. Sell-side analysts anticipate that Kiniksa Pharmaceuticals International will post 1.24 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, insider John F. Paolini sold 58,424 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the completion of the transaction, the insider owned 65,623 shares in the company, valued at $3,524,611.33. This trade represents a 47.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Michael R. Megna sold 6,625 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total transaction of $309,321.25. Following the completion of the transaction, the chief accounting officer owned 27,418 shares of the company’s stock, valued at approximately $1,280,146.42. This trade represents a 19.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 653,301 shares of company stock valued at $34,046,073. 51.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KNSA. EverSource Wealth Advisors LLC raised its holdings in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the last quarter. Osaic Holdings Inc. bought a new position in Kiniksa Pharmaceuticals International in the 2nd quarter valued at approximately $31,000. KBC Group NV bought a new position in Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $34,000. Smartleaf Asset Management LLC bought a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $41,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.